Pharming (PHAR) Consolidated Net Income (2020 - 2026)

Pharming (PHAR) has 7 years of Consolidated Net Income data on file, last reported at $28.0 million in Q2 2026.

• Quarterly Consolidated Net Income rose 397.58% year-over-year to $28.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $39.8 million (up 461.17% YoY) and the FY2025 annual result came in at $2.5 million, up 121.43% from the prior year.
• Consolidated Net Income grew to $28.0 million in Q2 2026, from -$14.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $37.9 million in Q4 2022 to a low of -$20.5 million in Q1 2024.
• A 5-year average of $2.1 million and a median of $757003.4 in 2024 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2023 — Consolidated Net Income plunged 603.58% — and 2025, when it jumped 1623.38%.
• Tracing PHAR's Consolidated Net Income over 5 years: stood at $37.9 million in 2022, then sank by 131.69% to -$12.0 million in 2023, then soared by 57.18% to -$5.1 million in 2024, then surged by 100.0% to $4.3 in 2025, then soared by 651371993.02% to $28.0 million in 2026.
• The last three Consolidated Net Income figures came in at $28.0 million (Q2 2026), -$14.3 million (Q1 2026), and $4.3 (Q4 2025), per Business Quant data.